Semaglutide Weight Loss & Diabetes: Key Guide

Overview

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the action of naturally occurring GLP-1 hormone. It reduces appetite, slows gastric emptying, and improves blood sugar control. Approved as Wegovy for weight management and Ozempic for type 2 diabetes.

Key Information

Mechanism

Activates GLP-1 receptors in the hypothalamus to suppress appetite, and in the pancreas to stimulate insulin secretion. Weekly dosing due to extended half-life (~7 days).

Benefits

• 14.9-15.8% weight loss
• Cardiovascular risk reduction
• Improved glycemic control
• Weekly dosing convenience

Side Effects

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Risk of pancreatitis

Contraindications

• Medullary thyroid carcinoma
• MEN2 syndrome
• Pregnancy

Evidence Summary

STEP 1-8 trials (6,000+ participants), SELECT trial (17,604 patients). Gold-standard evidence for obesity pharmacotherapy.

Research

STEP trials showed 14.9-15.8% mean weight loss over 68 weeks. SELECT trial demonstrated 20% reduction in MACE in non-diabetic obese patients with cardiovascular disease.

Safety

Boxed warning for thyroid C-cell tumors. Common side effects: nausea (44%), diarrhea (30%), vomiting (24%).

Semaglutide Weight Loss & Diabetes: Key Guide

Semaglutide is a long-acting GLP-1 drug. It acts like the natural GLP-1 hormone. It can lower appetite, slow stomach emptying, and improve blood sugar control. It is approved as Wegovy for weight control and Ozempic for type 2 diabetes.

Key Information

• Also known as Wegovy and Ozempic
• Sequence: H-Aib-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG-NH2
• CAS Number: 910463-57-3
• Molecular formula: C154H296N56O46
• Half-life: 7 days
• Administration: subcutaneous injection, oral tablet
• Dose range: 0.25-2.4 mg weekly
• Price range: $2.06-$25.99/mg
• Storage: keep cold at 2-8C
• Prep: pre-filled pen, no prep needed
• US status: FDA-approved
• Legal status: FDA-approved as Wegovy for weight and Ozempic for diabetes
• Patent-protected. No generic is available.
• Research papers: 3 indexed

How It Works

Semaglutide turns on GLP-1 receptors in the brain to lower appetite. It also acts on the pancreas to raise insulin release. Weekly dosing works because the half-life is long, about 7 days.

Benefits

• 14.9-15.8% weight loss
• Heart risk reduction
• Better blood sugar control
• Weekly use is easy

Semaglutide Side Effects

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Risk of pancreatitis

Do Not Use If

• Medullary thyroid carcinoma
• MEN2 syndrome
• Pregnancy

Evidence Summary

STEP 1-8 trials included more than 6,000 people. SELECT included 17,604 patients. This is strong evidence for obesity drug treatment.

Research

STEP trials showed 14.9-15.8% mean weight loss over 68 weeks. SELECT showed a 20% drop in major heart events (MACE) in non-diabetic obese patients with heart disease.

Safety

There is a boxed warning for thyroid C-cell tumors. Common semaglutide side effects include nausea, diarrhea, and vomiting. Review safety data and published studies before use.

Legal Status

FDA-approved as Wegovy for weight and Ozempic for diabetes. Patent-protected, and no generic is available.

Frequently Asked Questions About Semaglutide

What is Semaglutide?

Semaglutide is a research peptide also known as Wegovy and Ozempic. Semaglutide medication is a GLP-1 drug used for weight loss and diabetes care. It is also studied by research vendors.

How does Semaglutide work?

It turns on GLP-1 receptors in the brain and pancreas. This lowers appetite and boosts insulin release. Weekly dosing is possible because the half-life is about 7 days.

Does semaglutide work for weight loss?

Yes. Semaglutide for weight loss has shown strong results in trials. It works best with steady dosing and careful use in studies.

What is the recommended dosage for Semaglutide?

The common semaglutide dose is 0.25-2.4 mg each week. Semaglutide dosing for weight loss often starts low and rises slowly. Doses of semaglutide depend on the study goal. Start with published study data and conservative amounts. Semaglutide should only be used in controlled research settings.

Are semaglutide pills available?

Semaglutide pills are an oral form. Semaglutide medication comes as an injection or an oral tablet. Searches for semaglutide pills for weight loss and semaglutide pills weight loss are common, but the right dose should still come from published research.

Where can I buy Semaglutide?

PepsReview tracks semaglutide pricing from many vendors. Check the Vendors tab for a price table with cost per milligram, purity, COA status, and stock. User reviews are on each profile page.

Is Semaglutide legal?

US status: FDA-approved. It is approved as Wegovy for weight and Ozempic for diabetes. It is patent-protected, and no generic is available.

What are the side effects of Semaglutide?

Reported semaglutide side effects include nausea, diarrhea, vomiting, constipation, and pancreatitis risk. Review safety data and published studies before use.

Key Research Papers on Semaglutide

The peer-reviewed studies and clinical trials below are indexed in our research library. Each paper links to a summary with key findings, study design, and publication data.

• Wilding et al. 2021 — STEP 1: Semaglutide for Obesity — NEJM, 2021 (3200 citations)
• Ryan et al. 2023 — SELECT: Heart Outcomes — NEJM, 2023 (1200 citations)
• Garvey et al. 2022 — STEP 5: Lasting Weight Loss — JAMA, 2022 (850 citations)

Related Weight Loss / Metabolic Peptides

Other peptides in this group may be useful for comparison in research.

• Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
• Retatrutide — Triple agonist (GLP-1/GIP/Glucagon), next-gen weight loss
• Liraglutide — First-gen GLP-1 agonist, daily injection
• Survodutide — Dual GLP-1/glucagon agonist in development
• AOD-9604 — Modified growth hormone fragment for fat burning

Key Research Papers on Semaglutide Weight Loss & Diabetes: Key Guide

The following peer-reviewed studies and clinical trials are indexed in our research library for Semaglutide Weight Loss & Diabetes: Key Guide. Each paper links to a detailed summary with key findings, study design, and publication metadata.

• Wilding et al. 2021 — STEP 1: Semaglutide for Obesity — NEJM, 2021 (3200 citations)
• Ryan et al. 2023 — SELECT: Cardiovascular Outcomes — NEJM, 2023 (1200 citations)
• Garvey et al. 2022 — STEP 5: Sustained Weight Loss — JAMA, 2022 (850 citations)

Related Weight loss / Metabolic Peptides

Other peptides in the weight loss / metabolic category that may be of interest for comparative research: